GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -41.80% | -43.35% | -121.25% | -119.53% | 244.52% |
| Total Other Revenue | -13.37% | -15.60% | -56.09% | -59.61% | -9.73% |
| Total Revenue | -26.46% | -28.39% | -97.08% | -97.30% | 258.13% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -26.46% | -28.39% | -97.08% | -97.30% | 258.13% |
| SG&A Expenses | -8.22% | -10.62% | -5.31% | -12.95% | -41.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.89% | -44.38% | -21.04% | -27.40% | -28.28% |
| Operating Income | 44.64% | 46.09% | 3.29% | 11.09% | 33.91% |
| Income Before Tax | 32.02% | 33.80% | -25.89% | -15.74% | 43.50% |
| Income Tax Expenses | -72.94% | -73.86% | -288.89% | -274.07% | 872.73% |
| Earnings from Continuing Operations | 32.10% | 33.88% | -25.62% | -15.49% | 43.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.10% | 33.88% | -25.62% | -15.49% | 43.38% |
| EBIT | 44.64% | 46.09% | 3.29% | 11.09% | 33.91% |
| EBITDA | 42.32% | 43.83% | -3.59% | 4.77% | 29.19% |
| EPS Basic | 56.25% | 57.28% | 18.95% | 25.52% | 73.65% |
| Normalized Basic EPS | 56.22% | 57.20% | 18.57% | 25.42% | 73.76% |
| EPS Diluted | 56.25% | 57.28% | 18.95% | 25.52% | 73.65% |
| Normalized Diluted EPS | 56.22% | 57.20% | 18.57% | 25.42% | 73.76% |
| Average Basic Shares Outstanding | 54.84% | 54.84% | 55.01% | 55.01% | 115.12% |
| Average Diluted Shares Outstanding | 54.84% | 54.84% | 55.01% | 55.01% | 115.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |